Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects

Nature Communications

Volumn 6, Issue , 2015, Pages

  Zhang, Hongkai ^a   Sturchler, Emmanuel ^a   Zhu, Jiang ^a   Nieto, Ainhoa ^a   Cistrone, Philip A ^a   Xie, Jia ^a   He, Linling ^a   Yea, Kyungmoo ^b   Jones, Teresa ^a   Turn, Rachel ^a   Di Stefano, Peter S ^c   Griffin, Patrick R ^a   Dawson, Philip E ^a   McDonald, Patricia H ^a   Lerner, Richard A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SHANGHAITECH UNIVERSITY   (China)

^c Zebra Biologics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GUANINE NUCLEOTIDE BINDING PROTEIN; HEMOGLOBIN A1C; ANTIDIABETIC AGENT; GLP1R PROTEIN, MOUSE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; PEPTIDE;

DIABETES; FAT; HEMOGLOBIN; LIGAND; MOLECULAR ANALYSIS; PEPTIDE; PROTEIN; RODENT;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; FATTY LIVER; GLUCOSE TOLERANCE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INFLAMMATION; MOUSE; NONHUMAN; PEPTIDE LIBRARY; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GENETICS; MALE; METABOLISM; PATHOPHYSIOLOGY; PRECLINICAL STUDY;

MUS;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED C57BL; PEPTIDES;

EID: 84948843969     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9918     Document Type: Article

References (55)

1. Drucker, D. J. The biology of incretin hormones. Cell Metab. 3, 153-165 (2006).
2. Lamont, B. J. et al. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J. Clin. Invest. 122, 388-402 (2012).
3. Willard, F. S., Sloop, K. W. Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor. Exp. Diabetes Res. 2012, 470851 (2012).
4. Thorens, B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci. USA 89, 8641-8645 (1992).
5. Montrose-Rafizadeh, C. et al. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 140, 1132-1140 (1999).
6. Sonoda, N. et al. Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proc. Natl Acad. Sci. USA 105, 6614-6619 (2008).
7. Zhang, M. et al. Loss of beta-arrestin2 mediates pancreatic-islet dysfunction in mice. Biochem. Biophys. Res. Commun. 435, 345-349 (2013).
8. Freedman, N. J., Lefkowitz, R. J. Desensitization of G protein-coupled receptors. Recent. Prog. Horm. Res. 51, 319-351 (1996).
9. Luttrell, L. M. et al. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc. Natl Acad. Sci. USA 98, 2449-2454 (2001).
10. McDonald, P. H. et al. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 290, 1574-1577 (2000).
11. Urban, J. D. et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1-13 (2007).
12. Koole, C. et al. Minireview: signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery. Mol. Endocrinol. 27, 1234-1244 (2013).
13. Rajagopal, S., Rajagopal, K., Lefkowitz, R. J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373-386 (2010).
14. Montrose-Rafizadeh, C. et al. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J. Biol. Chem. 272, 21201-21206 (1997).
15. Gruber, C. W., Muttenthaler, M., Freissmuth, M. Ligand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptors. Curr. Pharm. Des. 16, 3071-3088 (2010).
16. Xie, J., Zhang, H., Yea, K., Lerner, R. A. Autocrine signaling based selection of combinatorial antibodies that transdifferentiate human stem cells. Proc. Natl Acad. Sci. USA 110, 8099-8104 (2013).
17. Nesterov, A. et al. Screening a plant extract library for inhibitors of cholecystokinin receptor CCK1 pathways. J. Biomol. Screen. 15, 518-527 (2010).
18. Hennen, S. et al. Decoding signaling and function of the orphan G proteincoupled receptor GPR17 with a small-molecule agonist. Sci. Signal. 6-93 (2013).
19. Lymperopoulos, A. et al. Different potencies of angiotensin receptor blockers at suppressing adrenal beta-Arrestin1-dependent post-myocardial infarction hyperaldosteronism. J. Am. Coll. Cardiol. 64, 2805-2806 (2014).
20. Winzell, M. S., Ahren, B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53(Suppl 3): S215-S219 (2004).
21. Meloni, A. R., DeYoung, M. B., Lowe, C., Parkes, D. G. GLP-1 receptor activated insulin secretion from pancreatic beta-cells: mechanism and glucose dependence. Diabetes Obes. Metab. 15, 15-27 (2013).
22. Barnes, K. M., Miner, J. L. Role of resistin in insulin sensitivity in rodents and humans. Curr. Protein Pept. Sci. 10, 96-107 (2009).
23. Song, H. et al. Resistin is regulated by C/EBPs, PPARs, and signal-transducing molecules. Biochem. Biophys. Res. Commun. 299, 291-298 (2002).
24. Toruner, F. et al. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats. Horm. Metab. Res. 36, 226-230 (2004).
25. Christiaens, V., Van Hul, M., Lijnen, H. R., Scroyen, I. CD36 promotes adipocyte differentiation and adipogenesis. Biochim. Biophys. Acta 1820, 949-956 (2012).
26. Farmer, S. R. Transcriptional control of adipocyte formation. Cell Metab. 4, 263-273 (2006).
27. Lumeng, C. N., Deyoung, S. M., Bodzin, J. L., Saltiel, A. R. Increased inflammatory properties of adipose tissue macrophages recruited during dietinduced obesity. Diabetes 56, 16-23 (2007).
28. Lumeng, C. N., Deyoung, S. M., Saltiel, A. R. Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am. J. Physiol. Endocrinol. Metab. 292, E166-E174 (2007).
29. Amori, R. E., Lau, J., Pittas, A. G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298, 194-206 (2007).
30. Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., Butler, P. C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141, 150-156 (2011).
31. Wootten, D. et al. Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands. Mol. Pharmacol. 83, 822-834 (2013).
32. Jorgensen, R., Kubale, V., Vrecl, M., Schwartz, T. W., Elling, C. E. Oxyntomodulin differentially affects glucagon-like peptide-1 receptor betaarrestin recruitment and signaling through Galpha(s). J. Pharmacol. Exp. Ther. 322, 148-154 (2007).
33. Carvalho, E., Kotani, K., Peroni, O. D., Kahn, B. B. Adipose-specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle. Am. J. Physiol. Endocrinol. Metab. 289, E551-E561 (2005).
34. Aitman, T. J. et al. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat. Genet. 21, 76-83 (1999).
35. Borst, S. E. The role of TNF-alpha in insulin resistance. Endocrine 23, 177-182 (2004).
36. Roberts, R. et al. Markers of de novo lipogenesis in adipose tissue: associations with small adipocytes and insulin sensitivity in humans. Diabetologia 52, 882-890 (2009).
37. Galic, S., Oakhill, J. S., Steinberg, G. R. Adipose tissue as an endocrine organ. Mol. Cell. Endocrinol. 316, 129-139 (2010).
38. Qatanani, M., Szwergold, N. R., Greaves, D. R., Ahima, R. S., Lazar, M. A. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J. Clin. Invest. 119, 531-539 (2009).
39. Schwartz, D. R., Lazar, M. A. Human resistin: found in translation from mouse to man. Trends Endocrinol. Metab. 22, 259-265 (2011).
40. Banerjee, R. R. et al. Regulation of fasted blood glucose by resistin. Science 303, 1195-1198 (2004).
41. Steppan, C. M. et al. The hormone resistin links obesity to diabetes. Nature 409, 307-312 (2001).
42. Okuno, A. et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101, 1354-1361 (1998).
43. Jun, L. S. et al. Absence of glucagon and insulin action reveals a role for the glucagon-like peptide-1 receptor in endogenous glucose production. Diabetes 64, 819-827 (2014).
44. Omar, B. A. et al. Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. Diabetes 63, 101-110 (2014).
45. Smith, E. P. et al. The role of beta cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab. 19, 1050-1057 (2014).
46. Vendrell, J. et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology 152, 4072-4079 (2011).
47. Challa, T. D. et al. Regulation of adipocyte formation by GLP-1/GLP-1R signaling. J. Biol. Chem. 287, 6421-6430 (2012).
48. Yang, J. et al. Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes. Int. J. Mol. Med. 31, 1429-1435 (2013).
49. Zhuang, L. N., Hu, W. X., Xin, S. M., Zhao, J., Pei, G. Beta-arrestin-1 protein represses adipogenesis and inflammatory responses through its interaction with peroxisome proliferator-activated receptor-gamma (PPARgamma). J. Biol. Chem. 286, 28403-28413 (2011).
50. Ceperuelo-Mallafre, V. et al. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. J. Clin. Endocrinol. Metab. 99, E908-E919 (2014).
51. Mohammad, S. et al. Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110beta isoform of phosphatidylinositol 3-kinase. J. Biol. Chem. 286, 43062-43070 (2011).
52. Kim, S. J., Nian, C., McIntosh, C. H. Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPARgamma and histone acetylation. J. Lipid Res. 52, 759-770 (2011).
53. Finan, B. et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med. 5, 209-151 (2013).
54. Schelshorn, D. et al. Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation. Mol. Pharmacol. 81, 309-318 (2012).
55. Rajagopal, S. et al. Quantifying ligand bias at seven-transmembrane receptors. Mol. Pharmacol. 80, 367-377 (2011).